A Food and Drug Administratin advisory panel rejected Forest Laboratories Inc.'s (NYSE: FRX) lung disease treatment Daxas citing the possibility of dangerous side effects sending the stock price tumbling $4.04 to $28.42.
FDA Panel Rejects Forest Labs' Lung Disease Treatment
April 08, 2010 at 13:50 PM EDT
